Mid Cap
Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| # | Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|---|
| 1 |
1
Alkermes
ALKS
$7.55B
| $7.55B | $44.94 | 2.69% |
|
| 2 |
2
Kiniksa Pharmaceuticals
KNSA
$7.38B
| $7.38B | $93.89 | 0.37% |
|
| 3 |
3
Amneal Pharmaceuticals
AMRX
$7.36B
| $7.36B | $21.12 | 1.26% |
|
| 4 |
4
Lantheus
LNTH
$6.68B
| $6.68B | $102.10 | 0% |
|
| 5 |
5
Supernus
SUPN
$5.94B
| $5.94B | $28.61 | 0.92% |
|
| 6 |
6
Liquidia
LQDA
$4.9B
| $4.9B | $54.43 | 3.88% |
|
| 7 |
7
Hims & Hers Health
HIMS
$3.42B
| $3.42B | $14.60 | 8.86% |
|
| 8 |
8
Amylyx Pharmaceuticals
AMLX
$3.35B
| $3.35B | $26.02 | 0.69% |
|
| 9 |
9
Xeris Biopharma Holdings
XERS
$3.1B
| $3.1B | $16.97 | 2.11% |
|
| 10 |
10
Bausch Health
BHC
$3.08B
| $3.08B | $8.22 | 3.97% |
|
| 11 |
11
Prestige Consumer Healthcare
PBH
$2.35B
| $2.35B | $49.63 | 0.06% |
|
| 12 |
12
HUTCHMED
HCM
$2.3B
| $2.3B | $13.22 | 1.71% |
|
| 13 |
13
Perrigo
PRGO
$2.21B
| $2.21B | $15.94 | 0.62% |
|
| 14 |
14
Regencell Bioscience
RGC
$2.07B
| $2.07B | $4.18 | 4.13% |
|
Mid Cap Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 14 mid cap Drug Manufacturers - Specialty & Generic stocks — companies in the Drug Manufacturers - Specialty & Generic industry with a market cap between $2B and $10B — worth a combined $61.7B.
The largest by market cap are Alkermes (ALKS) at $7.55B, Kiniksa Pharmaceuticals (KNSA) at $7.38B and Amneal Pharmaceuticals (AMRX) at $7.36B.
Among institutional investors, Kiniksa Pharmaceuticals (KNSA) drew the most net new fund positions in Q3 2026: 71 funds opened new positions, taking total fund holders up 40 (15%) quarter-over-quarter.
- Combined market cap: $61.7B across 14 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Alkermes (ALKS), $7.55B market cap.
- Most net new fund positions in Q3 2026: Kiniksa Pharmaceuticals (KNSA), +40 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.